Literature DB >> 519399

Long-term survival of patients with breast cancer: a study of the curability of the disease.

A O Langlands, S J Pocock, G R Kerr, S M Gore.   

Abstract

A retrospective analysis was made of 3878 cases of breast carcinoma first seen in Edinburgh from 1954 to 1964. During this time there was a policy to treat breast cancer by simple mastectomy and x-ray therapy, and over 90% of cases classified as international stages I and II were so treated. The mortality in these women was compared with that in an equivalent normal population using Scottish national age-specific death rates. For every year of follow-up within 20 years of initial treatment there was an excess mortality from all causes. There was an overall excess mortality of 58% among patients with breast cancer 15-20 years after initial treatment, and 20 times more deaths occurred in this period from breast cancer than in a normal population. For patients disease-free after 15 years there was still a 28% excess mortality from all causes. Factors known to be of major prognostic significance for five-year survivorship had less influence than might have been expected when the ratio of observed to expected deaths was considered for longer periods of follow-up. The effect of clinical staging (I, II, or III), though initially marked, largely disappeared by the 10th year of follow-up, and after allowing for age there was no evidence beyond 10 years of an effect on survival of the original stage of the disease. Similarly, the effect of tumour size on survival disappeared after 10 years. Women who were premenopausal at presentation still had a significant excess of deaths in the fourth quinquennium of follow-up. In the menopausal and postmenopausal groups combined there was still a small non-significant excess of deaths from all causes after 15 years but this almost disappeared when patients who had already relapsed were excluded. In terms of overall mortality only patients who have undergone the menopause before presentation and who are disease-free 15 years after primary treatment may prove to be cured by conventional techniques such as simple mastectomy and postoperative radiotherapy.

Entities:  

Mesh:

Year:  1979        PMID: 519399      PMCID: PMC1596940          DOI: 10.1136/bmj.2.6200.1247

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  15 in total

1.  Simple mastectomy and radiotherapy in the treatment of breast cancer.

Authors:  R McWHIRTER
Journal:  Br J Radiol       Date:  1955-03       Impact factor: 3.039

2.  Cancer of the female breast, mortality, and the menopause.

Authors:  A MCKENZIE
Journal:  Lancet       Date:  1955-11-26       Impact factor: 79.321

3.  Does the malignancy of breast cnacer vary with age?

Authors:  B A Stoll
Journal:  Clin Oncol       Date:  1976-03

4.  The curability of breast cancer.

Authors:  D Brinkley; J L Haybittle
Journal:  World J Surg       Date:  1977-05       Impact factor: 3.352

5.  Controlled trials in the treatment of "early" breast cancer: a review of published results.

Authors:  H J Stewart
Journal:  World J Surg       Date:  1977-05       Impact factor: 3.352

6.  Prognosis in breast cancer: the relevance of clinical staging.

Authors:  A O Langlands; G R Kerr
Journal:  Clin Radiol       Date:  1978-11       Impact factor: 2.350

7.  Observations on the mortality from carcinoma of the breast.

Authors:  J L Campos
Journal:  Br J Radiol       Date:  1972-01       Impact factor: 3.039

8.  Cancer of the breast: Its outcome as measured by the rate of dying and causes of death.

Authors:  C B Mueller; W Jeffries
Journal:  Ann Surg       Date:  1975-09       Impact factor: 12.969

9.  The curability of breast cancer.

Authors:  W Duncan; G R Kerr
Journal:  Br Med J       Date:  1976-10-02

10.  Breast cancer in 3,558 women: age as a significant determinant in the rate of dying and causes of death.

Authors:  C B Mueller; F Ames; G D Anderson
Journal:  Surgery       Date:  1978-02       Impact factor: 3.982

View more
  30 in total

1.  Timing of surgery during the menstrual cycle and prognosis of breast cancer.

Authors:  R A Badwe; I Mittra; R Havaldar
Journal:  J Biosci       Date:  2000-03       Impact factor: 1.826

2.  A joint hazard and time scaling model to compare survival curves.

Authors:  S Klawansky; M S Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 3.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

4.  Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer.

Authors:  P E Lønning; S I Helle; D C Johannessen; D Ekse; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Thirty-four year follow up of patients with breast cancer in clinical trial of postoperative radiotherapy.

Authors:  M K Palmer; G G Ribeiro
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-19

Review 6.  The menopause and breast cancer.

Authors:  F E Alexander; M M Roberts
Journal:  J Epidemiol Community Health       Date:  1987-06       Impact factor: 3.710

7.  Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years.

Authors:  A D Hibberd; L J Horwood; J E Wells
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-04

8.  Changes in long term prognosis for breast cancer in a Dutch cancer registry.

Authors:  H W Nab; W C Hop; M A Crommelin; H M Kluck; L H van der Heijden; J W Coebergh
Journal:  BMJ       Date:  1994-07-09

9.  Is follow up of patients after surgery for breast cancer worthwhile?

Authors:  M C Ormiston; A G Timoney; A R Qureshi
Journal:  J R Soc Med       Date:  1985-11       Impact factor: 5.344

10.  Charity Hospital experience with long-term survival and prognostic factors in patients with breast cancer with localized or regional disease.

Authors:  C M Sutherland; F J Mather
Journal:  Ann Surg       Date:  1988-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.